Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials
Year: 2021
Type: article
Source: Circulation
Authors: Stefan D. Anker, Piotr Ponikowski, Christoph Wanner, Egon Pfarr, Sibylle Hauske, Barbara Peil, Afshin Salsali, Ivana Ritter, Audrey Koitka-Weber, Martina Brueckmann, JoAnn Lindenfeld, William T. Abraham, on behalf of the EMPERIAL Investigators and National Coordinators
Institutions: Charité – Universitätsmedizin Berlin, Wroclaw Medical University, Universitätsklinikum Würzburg, Boehringer Ingelheim (Germany), Heidelberg University, University Medical Centre Mannheim, Rutgers, The State University of New Jersey, Boehringer Ingelheim (United States), Monash University, Vanderbilt University Medical Center, The Ohio State University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W3112794227